Vanderbilt Rapidly Accelerates Research Deal Making Targeting COVID-19 Including Access to Open-Source Research Opportunity

Jul 10, 2020 | Center for Technology Transfer & Commercialization, Investor Watch, News, Vanderbilt University

Vanderbilt Rapidly Accelerates Research Deal Making Targeting COVID-19 Including Access to Open-Source Research Opportunity

Vanderbilt researchers have pivoted a great deal of research activity toward addressing the COVID-19 pandemic. Vanderbilt’s Center for Technology Transfer & Commercialization (CTTC) has accelerated its services to facilitate three option/license agreements, 43 material transfer agreements (MTAs), and the filing of 11 patent applications in record time. In what typically takes up to nine months (complex license agreement) or up to 3 weeks for the MTA, now under the CTTS Vanderbilt is cranking deals out in as few as 10 days or 24 hours respectively. A show of dedication to directing innovation with commercial potential to the collective effort of fighting COVID-19.

Provisional Open Source

Vanderbilt’s CTTC is now offering open-source access for interested parties to support the identification of value-added research on a first-come, first-serve basis. Contracts are processed speedily to share researcher technology with as many parties as possible. Vanderbilt CTTC seeks to drive progress leveraging compelling research with the hopes of commercialization to purposeful products from these inventions.

COVID-19 MTAs

Vanderbilt CTTC reports that a majority of the MTAs facilitated by CTTC for addressing COVID-19 research were completed within 24 hours or less: undoubtedly record time if not near so. Jody Hankins, CTTC licensing officer of life science technologies made the spirit and intent of the office clear: “A delay in financiering an agreement was a delay in finding solutions to COVID-19, therefore it was imperative to negotiate these promptly for the betterment of human kind.”

Recent Deals

CTTC recently did a license deal with AstraZeneca and an option agreement with a biotech company named IDBiologics, which provided antibodies for use in development of therapeutics to treat COVID-19. CTTC also executed an agreement to enable manufacturing and resale antibodies by Leinco Technologies, a developer and manufacturer of leading-edge recombinant proteins, antibodies and conjugates for use in diagnostics and research applications. These license agreements originate from research conducted and discovered under the guidance of James Crowe, Jr., director of the Vanderbilt Vaccine Center (VCC), at Vanderbilt University Medical Center and Ann Scott Carell Professor of Pediatrics and Professor of Pathology, Microbiology and Immunology.

Alan Bentley, assistant vice chancellor of CTTC reports that the teams are expediting deal flow.

CTTC Continues to Produce

Vanderbilt’s CTTC has managed six COVID-19 related inventions ranging from software and therapeutics to vaccines and diagnostics; these have led to 11 patent applications via CTTC. And based on the National Academy of Inventors (NAI) and the Intellectual Property Owners Association (IPO), Vanderbilt is among the top 100 worldwide universities granted U.S. patents in 2019.

Call to Action: CTTC is reviewing numerous projects and ideas from Vanderbilt researchers that have the potential to yield additional industry partnerships. Interested in partnering? Contact CTTC

0 Comments

Pin It on Pinterest